RCMECredit materiality pre-analysisIncludes illustrative values
Analytical aid.Not a rating or rating recommendation. Public data only.

Cyber incident surveillance · analysis completed 2026-10-20 18:49:10 UTC

Boston Scientific

CIK 0000885725 · status watch · overall tier elevated. Within 9.3% of S&P's stated leverage level of 2.5x on the as-reported proxy (S&P adjustments not applied) basis; Business risk scores 4 of 5 (elevated); Liquidity risk scores 5 of 5 (severe).

Composite3.0/5 · Moderate
Score breakdownRisk profileFull reportEvidenceDimensionsAudit trail

FFO to debt (%, TTM)

S&P Corporate Methodology Table 17 band boundaries shown as horizontal lines.

60%45%30%2024-12-31: 27.6%2025-12-31: 35.9%24-0924-1225-0325-0625-0925-1226-0326-0663.2%24.4%

Source: SEC XBRL company facts; TTM through each quarter end, as-reported proxy (S&P adjustments not applied). derived (TTM through this quarter end, as-reported proxy)

Debt to EBITDA (x, TTM)

S&P Corporate Methodology Table 17 band boundaries shown as horizontal lines.

2x3x4x5xS&P stated level 2.5x2024-09-30: 2.9x2024-12-31: 2.8x2025-03-31: 2.7x2025-06-30: 2.6x2025-09-30: 2.4x2025-12-31: 2.3x2026-03-31: 2.1x2026-06-30: 2.3x24-0924-1225-0325-0625-0925-1226-0326-065.3x1.8x

Source: SEC XBRL company facts; TTM through each quarter end, as-reported proxy (S&P adjustments not applied). derived (TTM through this quarter end, as-reported proxy)